{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:14:48Z","timestamp":1775301288107,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bmcl.2020.127118","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T17:12:21Z","timestamp":1584637941000},"page":"127118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Discovery of heterocyclic carbohydrazide derivatives as novel selective fatty acid amide hydrolase inhibitors: design, synthesis and anti-neuroinflammatory evaluation"],"prefix":"10.1016","volume":"30","author":[{"given":"Yanguo","family":"Shang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaixuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengting","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2020.127118_b0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/acs.jmedchem.6b00538","article-title":"Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors","volume":"60","author":"Tuo","year":"2017","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127118_b0015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.bmc.2016.11.025","article-title":"1-Heteroarylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability","volume":"25","author":"Zahov","year":"2017","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127118_b0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbalip.2005.08.010","article-title":"Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages","volume":"1736","author":"Sun","year":"2005","journal-title":"Biochim Biophys Acta."},{"issue":"2","key":"10.1016\/j.bmcl.2020.127118_b0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol Rev"},{"issue":"9","key":"10.1016\/j.bmcl.2020.127118_b0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2009.06.006","article-title":"The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants","volume":"30","author":"Hill","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.bmcl.2020.127118_b0035","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.bmcl.2014.01.064","article-title":"1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase","volume":"24","author":"Keith","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2020.127118_b0040","unstructured":"Piomelli D. The endocannabinoid system: a drug discovery perspective. Current opinion in investigational drugs (London, England : 2000). 2005;6(7): 672-679."},{"key":"10.1016\/j.bmcl.2020.127118_b0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0074-7742(09)85005-8","article-title":"The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs","volume":"85","author":"Gaetani","year":"2009","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.bmcl.2020.127118_b0050","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.biopha.2018.08.125","article-title":"Scaffold hopping-guided design of some isatin based rigid analogs as fatty acid amide hydrolase inhibitors: Synthesis and evaluation","volume":"107","author":"Jaiswal","year":"2018","journal-title":"Biomedicine & pharmacotherapy = Biomedicine & pharmacotherapie."},{"issue":"2","key":"10.1016\/j.bmcl.2020.127118_b0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bmcl.2018.11.048","article-title":"Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model","volume":"29","author":"Bhuniya","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.bmcl.2020.127118_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-017-0568-7","article-title":"The Fatty Acid Amide Hydrolase Inhibitor URB937 Ameliorates Radiation-Induced Lung Injury in a Mouse Model","volume":"40","author":"Li","year":"2017","journal-title":"Inflammation."},{"issue":"11","key":"10.1016\/j.bmcl.2020.127118_b0065","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.chembiol.2005.08.011","article-title":"Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes","volume":"12","author":"Alexander","year":"2005","journal-title":"Chem Biol"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127118_b0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","article-title":"Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial","volume":"6","author":"D'Souza","year":"2019","journal-title":"The lancet Psychiatry."},{"key":"10.1016\/j.bmcl.2020.127118_b0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2017.10.007","article-title":"In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor","volume":"815","author":"Watabiki","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.bmcl.2020.127118_b0080","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cts.12548","article-title":"Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers","volume":"11","author":"Postnov","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.bmcl.2020.127118_b0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejmech.2018.10.021","article-title":"Tetrazolylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability","volume":"160","author":"Garzinsky","year":"2018","journal-title":"Eur J Med Chem."},{"issue":"6","key":"10.1016\/j.bmcl.2020.127118_b0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jcph.889","article-title":"The Bial 10\u20132474 Phase 1 Study-A Drug Development Perspective and Recommendations for Future First-in-Human Trials","volume":"57","author":"Chaikin","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"6342","key":"10.1016\/j.bmcl.2020.127118_b0095","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aaf7497","article-title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10\u20132474","volume":"356","author":"van Esbroeck","year":"2017","journal-title":"Science"},{"issue":"39","key":"10.1016\/j.bmcl.2020.127118_b0100","doi-asserted-by":"crossref","first-page":"37393","DOI":"10.1074\/jbc.M303922200","article-title":"Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase","volume":"278","author":"McKinney","year":"2003","journal-title":"The Journal of biological chemistry."},{"issue":"5599","key":"10.1016\/j.bmcl.2020.127118_b0105","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1126\/science.1076535","article-title":"Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling","volume":"298","author":"Bracey","year":"2002","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.bmcl.2020.127118_b0110","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1016\/j.bmcl.2011.08.055","article-title":"Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds","volume":"21","author":"Meyers","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127118_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-2010-1414","article-title":"Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation","volume":"21","author":"Hensley","year":"2010","journal-title":"Journal of Alzheimer's disease : JAD."},{"key":"10.1016\/j.bmcl.2020.127118_b0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.bmcl.2020.127118_b0130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejmech.2012.03.044","article-title":"Quinazoline-tyrphostin as a new class of antitumor agents, molecular properties prediction, synthesis and biological testing","volume":"53","author":"Alafeefy","year":"2012","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmcl.2020.127118_b0135","unstructured":"(E)-N'-(4-((3-fluorobenzyl)oxy)benzylidene)-1H-benzo[d]imidazole-2-carbohydrazide(26) ; 1H NMR (300 MHz, DMSO-d6) \u03b4 11.17 (s, 1H), 7.85 (s, 1H), 7.53 (t, J = 8.5 Hz, 4H), 7.21 (d, J = 7.6 Hz, 4H), 6.99 (dd, J = 8.7, 3.5 Hz, 4H), 5.08 (s, 2H). 13C NMR (400 MHz, DMSO-d6) \u03b4 172.19, 165.81, 163.86, 161.44, 159.95, 159.75, 142.70, 140.23, 140.16, 131.00, 130.92, 128.99, 128.64, 127.74, 124.02, 115.59, 115.22, 115.02, 114.85, 114.63, 68.89. HRMS(ESI) m\/z calculated for C15H11FN4O [M+1]+: 389.1257, found 389.1262."},{"key":"10.1016\/j.bmcl.2020.127118_b0140","unstructured":"BV2 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum under 37\u00b0C and 5% CO2. Cells were seeded at 2\u00d7105 cells per well in 96-well plates and incubated overnight. Following, inhibitor was added into the cell culture, and incubated for another 24 h. Each well was added LPS to a concentration of 50 ng\/mL and cells were continuously maintained for another 6 h. Then TNF-\u03b1 or IL-1\u03b2 was measured by ELISA method."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20302079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20302079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:32:58Z","timestamp":1760772778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X20302079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0960894X20302079"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127118","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of heterocyclic carbohydrazide derivatives as novel selective fatty acid amide hydrolase inhibitors: design, synthesis and anti-neuroinflammatory evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127118"}}